Sign in
Taking people in United StatesPhase 4

Isturisa for Mild Autonomous Cortisol Secretion, an Adrenal Condition

Tests Isturisa in adults with mild autonomous cortisol secretion.

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, United StatesSee the site
Trial code
Registry title
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Status
Recruiting
Phase
Phase 4
People taking part
10 people, planned
Started
2 Feb 2026
Expected to end
Mar 2029
Type of study
Interventional
Treatments tested
  • Osilodrostat (Isturisa)
Record updated
23 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild autonomous cortisol secretion (MACS), a mild form of Cushing's syndrome, who also have prediabetes or diabetes, high blood pressure, or obesity, and an adrenal adenoma or hyperplasia.

Age
Older than 18 years
Sex
All sexes
Disease stage
Mild autonomous cortisol secretion confirmed by at least two abnormal 1 mg dexamethasone suppression tests (cortisol >1.8 ug/dL) and at least two early morning fasting ACTH levels <15 pg/mL. At least one comorbidity: prediabetes or type 2 diabetes, systolic blood pressure of 130 mmHg or higher, or BMI >30 kg/m2. An adrenal adenoma or hyperplasia seen on CT or MRI.
Earlier treatment
No treatment for MACS within 12 weeks before screening and during the study, including metyrapone, mifepristone, ketoconazole, fluconazole or any investigational drug for hypercortisolism.
Biomarker or test result
Cortisol >1.8 ug/dL after 1 mg dexamethasone; ACTH <15 pg/mL. Prediabetes or diabetes: fasting glucose 100 mg/dL (5.6 mmol/L) or higher, 2-hour OGTT glucose 140 mg/dL (7.8 mmol/L) or higher, or HbA1c 5.7% (39 mmol/mol) or higher.

Main reasons for not taking part

  • Severe uncontrolled high blood pressure (SBP >170 mm Hg or DBP >110 mm Hg)
  • Poorly controlled diabetes (HbA1c >11% (97 mmol/mol))
  • Abnormal liver tests or severe kidney problems
  • Adrenal cancer or images suspicious for cancer, or plans for adrenal surgery
  • Pregnant, breastfeeding, or planning pregnancy in the next 2 years

The registry criteria, word for word

Show all 18 criteriaShow less

Who cannot take part

  • Has used or plans to use any treatments for MACS within 12 weeks before Screening and throughout the study, including metyrapone, mifepristone, ketoconazole, fluconazole, or any investigational drug for the treatment of hypercortisolism
  • Has severe, uncontrolled hypertension (mean SBP >170 mm Hg or mean Diastolic Blood Pressure (DBP) >110 mm Hg at Screening)
  • Has severe renal insufficiency (glomerular filtration rate ≤29 mL/min at Baseline)
  • Has adrenocortical carcinoma, or the adrenal images are suspicious for an underlying malignancy
  • Has poorly controlled DM (HbA1c >11% at Screening)
  • Has abnormal liver test results (total bilirubin >1.5×ULN or elevated alanine aminotransferase or aspartate aminotransferase >3×ULN at Baseline)
  • Has prolonged QT interval corrected for heart rate using Fridericia's equation (QTcF) (>450 ms for men and >470 ms for women) with a normal QRS interval (<120 ms) or QTcF interval >500 ms with wide QRS interval (≥120 ms)
  • Female patients of childbearing potential who cannot use a highly effective method of contraception, including all women <50 years old, women whose surgical sterilization was performed <6 months ago
  • Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism
  • Has persistent atrial fibrillation
  • Has uncorrected hypokalemia
  • Has autonomous co-secretion of aldosterone
  • Has plans for adrenalectomy or nodulectomy during the study
  • Pregnancy, lactating, or intends to become pregnant in the next 2 years

Other criteria

  • Age >18 years old with confirmed mild autonomous cortisol secretion (MACS) Cushing's syndrome, defined by:; At least two abnormal 1 mg Dexamethasone suppression tests (Cortisol > 1.8 ug/dL at 8-9 am after taking 1 mg dexamethasone at 11 pm) with appropriate dexamethasone level for the assay (last level within 3 months before enrollment); Having at least two early morning fasting ACTH <15 pg/mL (last level within 3 months before enrollment)
  • Presence of at least one of the following comorbidities:; The presence of prediabetes or Type 2 diabetes mellitus (T2DM): fasting plasma glucose ≥100 mg/dL and/or 2-hour Oral Glucose Tolerance Test (OGTT) glucose ≥140 mg/dL, or HbA1c ≥5.7%; Systolic hypertension is defined as a mean Systolic Blood Pressure (SBP) ≥130 mmHg after 5 min rest in a seated position (mean of 3 blood pressure measurements 5 minutes apart) irrespective of the number of anti-hypertensive medications; BMI >30 kg/m2
  • The presence of an adrenal adenoma or hyperplasia, as determined by CT or MRI studies
  • Negative urine pregnancy test at Baseline (urine) for women of childbearing potential

Where in United States

  • Johns Hopkins University School Of MedicineBaltimore, United StatesContact: Amir Hamrahian, MDTaking people

About the trial

What the trial wants to find out

To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.

The group in the trial

  • Isturisa Treatment ArmTreatment being tested

    Participants diagnosed with Mild Autonomous Cortisol Secretion (MACS) will receive Osilodrostat (Isturisa) as an investigational treatment. The intervention aims to evaluate comorbidities associated with MACS after the initiation of osilodrostat(Isturisa).

    Treatment: Osilodrostat (Isturisa)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Isturisa in Management of Mild Autonomous Cortisol Secretion (MACS)
Plain-language title
Isturisa for Mild Autonomous Cortisol Secretion, an Adrenal ConditionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 October 2026